rethinkPeptides Search
Menu
Research citation

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

International journal of clinical pharmacy

Citation

Seijas-Amigo, Jose; Salgado-Barreira, Ángel; Rodriguez-Penas, Diego; Cardeso-Paredes, Begoña; Ribeiro-Ferreiro, Marta; Rodriguez-Mañero, Moisés; Gonzalez-Juanatey, Jose Ramon. (2026). Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.. International journal of clinical pharmacy. https://doi.org/10.1007/s11096-026-02099-y